Scancell is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications. ImmunoBody is a DNA vaccine which stimulates high avidity anti-tumour T-cells for use as a monotherapy or in combination with checkpoint inhibitors. Moditope targets modified antigens and stimulates powerful anti-tumour T-cell responses for use in advanced and hard-to-treat cancers. Scancell has released new survival data for its Phase I/II in melanoma, with 69% recurrence-free survival after 3 years. Eight patients have now reached the 5 year survival, with four with no disease relapse.
If you'd like to be introduced to the team at Scancell Holdings, get in touch.Request a meeting